Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

09.12.20	Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer (GlobeNewswire)
09.12.20	Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer (GlobeNewswire)
08.12.20	Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial (GlobeNewswire)
05.12.20	Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas (GlobeNewswire)
04.12.20	Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD (GlobeNewswire)
24.11.20	Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event (GlobeNewswire)
19.11.20	Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy (GlobeNewswire)
19.11.20	New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases (GlobeNewswire)
19.11.20	Novartis set to achieve 100% renewable electricity in its European operations (GlobeNewswire)
13.11.20	New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender (GlobeNewswire)
06.11.20	Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS) (GlobeNewswire)
05.11.20	Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study (GlobeNewswire)
02.11.20	Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention (GlobeNewswire)
30.10.20	Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia (GlobeNewswire)
28.10.20	Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 (GlobeNewswire)
27.10.20	Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance. (GlobeNewswire)
27.10.20	Novartis im 3. Qu. mit solider Performance: operatives Kernergebnis steigt um 11%, Nettoumsatz auf Vorjahresniveau, starke Pipeline-Fortschritte; Jahresprognose für operatives Kernergebnis angehoben (GlobeNewswire)
26.10.20	Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G) (GlobeNewswire)
16.10.20	Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol (GlobeNewswire)
01.10.20	Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement (GlobeNewswire)
23.09.20	Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program (GlobeNewswire)
23.09.20	Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program (GlobeNewswire)
19.09.20	Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation (GlobeNewswire)
19.09.20	Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma (GlobeNewswire)
16.09.20	Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM (GlobeNewswire)
16.09.20	Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond (GlobeNewswire)
14.09.20	European Medicines Agency (EMA) approves safety label update for Novartis Beovu® (GlobeNewswire)
14.09.20	Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME) (GlobeNewswire)
11.09.20	Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS) (GlobeNewswire)
11.09.20	Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis (GlobeNewswire)
08.09.20	Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum (GlobeNewswire)
07.09.20	Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings (GlobeNewswire)
01.09.20	Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality (GlobeNewswire)
30.08.20	Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran (GlobeNewswire)
29.08.20	Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH) (GlobeNewswire)
26.08.20	Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study (GlobeNewswire)
26.08.20	Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study (GlobeNewswire)
22.08.20	Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma (GlobeNewswire)
22.08.20	Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma (GlobeNewswire)
20.08.20	FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis (GlobeNewswire)
17.08.20	Novartis announces US District Court for the District of Delaware upholds validity of Gilenya® (fingolimod) dosage regimen patent (GlobeNewswire)
05.08.20	Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis (GlobeNewswire)
04.08.20	Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma (GlobeNewswire)
03.08.20	Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis (GlobeNewswire)
03.08.20	Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis (GlobeNewswire)
27.07.20	Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe (GlobeNewswire)
24.07.20	Novartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease (GlobeNewswire)
21.07.20	Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales. (GlobeNewswire)
21.07.20	Novartis erzielte im ersten Halbjahr eine starke Performance. Die Jahresprognose 2020 für das operative Kernergebnis bzw. den Umsatz wurde am oberen bzw. unteren Ende früherer Voraussagen bestätigt. (GlobeNewswire)
16.07.20	Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19 (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
18:01		Börse New York in Grün: So steht der NASDAQ 100 aktuell
17:58		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
17:58		Handel in Europa: STOXX 50 schliesst im Minus
17:58		Schwacher Handel: SMI schliesst mit Verlusten
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter
17:58		SPI-Handel aktuell: SPI zum Handelsende leichter